Kynurenine Pathway

The Metabolite Cascade#

From kynurenine, the pathway branches into neuroprotective and neurotoxic arms:

Neuroprotective Branch#

• Kynurenic acid (KA): Produced by kynurenine aminotransferases (KATs). An NMDA receptor antagonist and alpha-7 nicotinic receptor antagonist. Neuroprotective at physiological concentrations; anti-excitotoxic. Depleted in ASD fecal samples.^{[1]Aziz-Zadeh 2025 — Relationships Between Brain Activity, Tryptophan-Related Gut Metabolites, and Autism SymptomatologyLisa Aziz-Zadeh, Sofronia M. Ringold, Aditya Jayashankar et al. · 2025Open reference 1 ↓}

The KA/QUIN Ratio#

The ratio of kynurenic acid to quinolinic acid serves as a functional readout of the pathway's net effect. In health, this ratio favors neuroprotection. Inflammation shifts it toward neurotoxicity by.

Upregulating IDO (increasing total pathway flux). Activating KMO in macrophages/microglia (directing flux toward the 3-HK/QUIN branch). Reducing KAT activity in astrocytes (diminishing the protective KA branch).

The Tryptophan Steal#

When IDO is chronically activated by inflammation, it creates a "tryptophan steal"—diverting substrate away from serotonin synthesis and toward kynurenine metabolites. This produces a dual insult. Serotonin depletion: Reduced substrate for TPH1/TPH2, contributing to mood and gastrointestinal dysfunction.

Neurotoxin accumulation: Elevated QUIN and 3-HK in the CNS.

This mechanism explains why anti-inflammatory strategies can improve depressive symptoms even without directly targeting serotonin—by reducing IDO induction, they restore the tryptophan balance.^{[2]Current Perspectives on Gut Microbiome Dysbiosis and DepressionCapuco A, Urits I, Hasoon J et al. · 2020Open reference 2 ↓}

Disease Involvement#

Depression#

IDO-mediated tryptophan depletion is well-documented in inflammatory depression. Patients treated with IFN-alpha (for hepatitis C or cancer) develop depressive symptoms that correlate with kynurenine/tryptophan ratios, not with serotonin depletion per se.^{[2]Current Perspectives on Gut Microbiome Dysbiosis and DepressionCapuco A, Urits I, Hasoon J et al. · 2020Open reference 2 ↓}

Schizophrenia#

Elevated kynurenic acid in cerebrospinal fluid is a consistent finding. As an NMDA antagonist, KA may contribute to the glutamatergic hypofunction underlying cognitive deficits and negative symptoms. This has led to the "kynurenine hypothesis" of schizophrenia.^{[3]The Gut Microbiome and Schizophrenia: The Current State of the Field and Clinical ApplicationsSzeligowski T, Yun AL, Lennox BR et al. · 2020Open reference 3 ↓[4]Ahmed 2024 — The Role of Infections and Inflammation in Schizophrenia: Review of the EvidenceGellan K Ahmed, Haidi Karam-Allah Ramadan, Khaled Elbeh et al. · 2024Open reference 4 ↓}

Neurodegenerative Diseases#

QUIN accumulation around amyloid plaques is documented in Alzheimer's Disease. QUIN promotes tau-phosphorylation and Amyloid-Beta aggregation. In Parkinson's Disease, kynurenine pathway metabolites contribute to dopaminergic neuron vulnerability.^{[5]Effects of gut microbiota on neurodegenerative diseasesKhatoon S, Kalam N, Rashid S et al. · 2023Open reference 5 ↓[6]Microbial Metallomics and Parkinson's Disease: A Unified Metal-Driven Framework Linking Ferroptosis, Dysbiosis, and alpha-Synuclein PathologyKaren Pendergrass · 2025Open reference 6 ↓}

Cerebral Palsy and Epilepsy#

Tryptophan-kynurenine pathway remodeling occurs in cerebral palsy with comorbid epilepsy, reflecting the convergence of neuroinflammation and metabolic disruption.^{[7]Peng 2023 — Gut Microbiome and Brain Metabolic Remodeling in CP with EpilepsyPeng A, et al. · 2023Open reference 7 ↓}

PMDD#

Kynurenine pathway alterations are implicated in the neuroinflammatory component of premenstrual dysphoric disorder, where cyclical hormonal changes modulate IDO activity.^{[8]Cheng 2025 — Neuroinflammation in PMS and PMDD (Review)Cheng et al. · 2025Open reference 8 ↓}

Cross-References#

• Tryptophan—the pathway's substrate
• Tryptophan Metabolism—comprehensive overview of all three tryptophan routes
• Iron—cofactor for IDO/TDO
• Neuroinflammation—the driver and consequence of pathway activation
• oxidative stress—QUIN and 3-HK generate ROS
• tau-phosphorylation—QUIN promotes tau pathology
• Amyloid-Beta—QUIN promotes aggregation
• Gut-Brain Axis—the route by which peripheral IDO activity affects the brain
• inflammation—the master activator of IDO